The GDP dissociation inhibitor 1 (GDI1) antibody is a tool used to study the GDI1 protein, which belongs to the Rab GDP-dissociation inhibitor (GDI) family. GDI1 regulates Rab GTPases, key players in intracellular vesicle trafficking. By binding to Rab proteins in their inactive GDP-bound state, GDI1 prevents nucleotide exchange and ensures their proper recycling between membranes and the cytosol. This function is critical for maintaining vesicle transport, organelle organization, and membrane dynamics in eukaryotic cells.
GDI1 antibodies are widely employed in research to detect protein expression, localization, and interactions via techniques like Western blotting, immunofluorescence, and immunoprecipitation. They have been instrumental in studies linking GDI1 dysfunction to neurological disorders, particularly X-linked intellectual disability syndrome (XLID) caused by GDI1 mutations. Additionally, altered Rab-GDI pathways are implicated in cancers and neurodegenerative diseases like Alzheimer’s, making these antibodies valuable for exploring disease mechanisms.
Commercially available GDI1 antibodies are typically raised against specific epitopes, with validation data confirming reactivity across human, mouse, and rat samples. Researchers rely on them to dissect GDI1’s role in cellular homeostasis and pathology, bridging molecular insights with therapeutic development.